Related Experiment Videos
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
1University of Washington Regional Primate Research Center, Seattle 98195, USA.
Abstract:
The efficacy of pre- and postexposure treatment with the antiviral compound (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV). PMPA was administered subcutaneously once daily beginning either 48 hours before, 4 hours after, or 24 hours after virus inoculation. Treatment continued for 4 weeks and the virologic, immunologic, and clinical status of the macaques was monitored for up to 56 weeks. PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected. These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.
Insights
Pre- and postexposure treatment with the antiviral PMPA effectively prevented simian immunodeficiency virus (SIV) infection in macaques. This study suggests PMPA
Area of Science:
- Virology
- Immunology
- Primatology
Background:
- Simian immunodeficiency virus (SIV) serves as a crucial animal model for studying human immunodeficiency virus (HIV).
- Antiviral compounds are critical for managing and preventing lentiviral infections.
- Understanding postexposure prophylaxis (PEP) is vital for mitigating HIV transmission risks.
Purpose of the Study:
- To evaluate the efficacy of (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) as a pre- and postexposure treatment against SIV infection.
- To assess the safety and antiviral activity of PMPA in a macaque model.
- To determine the potential of PMPA for early HIV infection prophylaxis.
Main Methods:
- Macaques were administered PMPA subcutaneously once daily, starting 48 hours before, 4 hours after, or 24 hours after SIV inoculation.
- Treatment duration was 4 weeks.
- Virologic, immunologic, and clinical parameters were monitored for up to 56 weeks.
Main Results:
- PMPA completely prevented SIV infection in all treated macaques.
- No toxicity was observed in macaques receiving PMPA.
- All control macaques that did not receive PMPA became infected with SIV.
Conclusions:
- PMPA demonstrates potent antiviral activity against SIV in a macaque model.
- PMPA is a safe and effective prophylactic agent for preventing early lentiviral infection.
- These findings support the potential use of PMPA for postexposure prophylaxis against HIV in humans.